RedHill Biopharma Wins $10M Court Appeal Against Kukbo

TL;DR

RedHill just won a $10M court appeal against Kukbo, securing a major judgment.

AI Summary

RedHill Biopharma Ltd. announced on September 29, 2025, that it won a New York Supreme Court appeal, upholding a $10 million summary judgment against Kukbo. This ruling confirms RedHill's entitlement to the judgment amount.

Why It Matters

This legal victory reinforces RedHill's financial claims, potentially impacting its cash position and future strategic decisions.

Risk Assessment

Risk Level: medium — While a legal win is positive, the actual collection of the $10 million and potential further appeals introduce ongoing uncertainty.

Key Numbers

• $10 million — Summary Judgment (Amount awarded to RedHill Biopharma after appeal.)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• Kukbo (company) — Defendant in legal case
• $10 million (dollar_amount) — Summary judgment amount
• New York Supreme Court (company) — Court that upheld the appeal

FAQ

Key Financial Figures

• $10 Million — ew York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo". This
• $10 million — RedHill has been granted approximately $10 million in total awards comprised of the $8.25
• $8.25 million — illion in total awards comprised of the $8.25 million original award and a subsequent $1.82
• $1.82 million — llion original award and a subsequent $1.82 million award for legal costs and expenses (inc

Filing Documents

• zk2533819.htm (6-K) — 27KB
• image00001.jpg (GRAPHIC) — 308KB
• 0001178913-25-003401.txt ( ) — 453KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 29, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill -- The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defense again, further ruling that RedHill had fulfilled its agreement obligations even after Kukbo's breach -- RedHill has been granted approximately $10 million in total awards comprised of the $8.25 million original award and a subsequent $1.82 million award for legal costs and expenses (including 9% statutory interest accrual) RALEIGH, N.C., and TEL-AVIV, Israel, September 29, 2025 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that The New York Supreme Court has, on appeal, upheld its original summary judgment ruling and award in favor of RedHill, unequivocally dismissing, once again, the entirety of Kukbo Co. Ltd's ("Kukbo") defense, ruling that Kukbo was in breach of both the original subscription agreement and subsequent exclusive license agreements with the Company (the "Agreements"). In making its appeal judgment, the New York Supreme Court clearly stated that RedHill had properly fulfilled its obligations according to the Agreements, even after Kukbo's non-payment breach. RedHill has been granted approximately $10 million in total awards from related court actions, comprised of the $8.25 million original award and a subsequent $1.82 million award for legal costs and expenses (including 9% ongoing statutory interest accrual).

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk of market and other con

View Full Filing

View this 6-K filing on SEC EDGAR